I n the developed countries of the world, life expectancy has prolonged continuously and the proportion of elderly peo ple increased steeply during the last decades. Decreased physical activity and decreased energy expenditure with aging predispose to fat accumulation. Therefore, obesity and the related comorbidities are considered as major health care problems in the elderly.
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Metabolic syndrome (MetS) is defined as a cluster of cardio metabolic risk factors, such as abdominal obesity, impaired glucose tolerance, dyslipidemia, and hypertension, which are related to insulin resistance. The degree of insulin resistance increases with aging. Therefore, elder people are at a greater risk to develop the MetS. Several populationbased studies have reported that MetS was associated with the risk of car diovascular disease (CVD) in people aged 65 years or older. 1 However, less evidence is available on the diverse effects of MetS on CVD between early (65-74 years) and late elderly (≥75 years) people.
Blood pressurelowering therapy has been acknowledged to be effective for preventing CVD. The treatment benefits have found to be broadly consistent among antihypertensive agents in middleaged and elder people. 2 With regard to late elderly people, the results of the HYpertension in the Very Elderly Trial (HYVET) showed that blood pressurelowering therapy in people 80 years of age was beneficial for preventing CVD. 3 Likewise, in the post-hoc analysis of the Action in Diabetes and Vascular disease: preterAx and diamicroNMR Controlled Evaluation (ADVANCE) study, antihypertensive treatment also reduced the risk of CVD in people aged ≥75 years with type 2 diabetes. 4 However, the favor effects of blood pressure lowering on CVD and optimal target levels of blood pressure control in the elderly are still inconclusive.
In this issue, Kawano et al. 5 present a post-hoc analysis of the Japanese Trial to Assess Optimal Systolic blood pressure in elderly hypertensive patients (JATOS), which is an open labeled randomized clinical trial to compare the effect of strict bloodpressuretreatment of <140 mmHg with that of mild bloodpressuretreatment of 140-159 mmHg on the develop ment of CVD in elderly hypertensive patients. The investigators show that MetS is associated with the greater risk of CVD in the mild bloodpressuretreatment group for the early elderly people, whereas the harmful effect of MetS on the risk of CVD disappears in the strict bloodpressuretreatment group, raising the possibility that strict bloodpressurecontrol is effective for reducing cardiovascular risk in early elderly people with MetS. On the contrary, MetS is not a significant risk factor for CVD in both strict and mild bloodpressuretreatment groups.
This study may not provide a conclusive evidence of the effect of MetS on CVD in the early and late elderly, because the generalizablity of the findings in the selected population, as with many clinical trials, is limited. These findings, how ever, let us reaffirm the necessity of largescale longitudinal studies to determine whether MetS contributes to the devel opment of CVD in the elderly, especially in the late elderly. In addition, further clinical trials to determine optimal con trol levels of blood pressure for preventing CVD in the elderly seem justified. 
